Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Elevation Oncology Inc. (NASDAQ: ELEV) Leading the Way in Friday Trading Based on Percentage Gain By: Investor Brand Network May 26, 2023 at 12:02 PM EDT Elevation Oncology Inc (NASDAQ: ELEV) is one of today’s top gainers. The company’s shares are currently up 62.46% on the day to $4.89. Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company’s lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. So far today, approximately 51.71M shares of Elevation Oncology Inc have been exchanged, as compared to an average 30-day volume of 852.5k shares. Elevation Oncology Inc share prices have moved between a 52-week high of $5.1 and a 52-week low of $0.72. The stock has moved -1.55% over the past week. To learn more about Elevation Oncology Inc, visit the company’s website at https://elevationoncology.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Elevation Oncology Inc. (NASDAQ: ELEV) Leading the Way in Friday Trading Based on Percentage Gain By: Investor Brand Network May 26, 2023 at 12:02 PM EDT Elevation Oncology Inc (NASDAQ: ELEV) is one of today’s top gainers. The company’s shares are currently up 62.46% on the day to $4.89. Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company’s lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. So far today, approximately 51.71M shares of Elevation Oncology Inc have been exchanged, as compared to an average 30-day volume of 852.5k shares. Elevation Oncology Inc share prices have moved between a 52-week high of $5.1 and a 52-week low of $0.72. The stock has moved -1.55% over the past week. To learn more about Elevation Oncology Inc, visit the company’s website at https://elevationoncology.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com
Elevation Oncology Inc (NASDAQ: ELEV) is one of today’s top gainers. The company’s shares are currently up 62.46% on the day to $4.89. Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company’s lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. So far today, approximately 51.71M shares of Elevation Oncology Inc have been exchanged, as compared to an average 30-day volume of 852.5k shares. Elevation Oncology Inc share prices have moved between a 52-week high of $5.1 and a 52-week low of $0.72. The stock has moved -1.55% over the past week. To learn more about Elevation Oncology Inc, visit the company’s website at https://elevationoncology.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com